Sandoz Files Petitions for IPR on Two Abbvie Adalimumab Patents

Sandoz has filed two petitions for IPR challenging Abbvie patents related to use of an antibody identified in the petitions as Humira® (adalimumab):  IPR2017-01987 challenging U.S. Patent 8,911,737, directed to methods of treating Crohn’s disease, and IPR2017-01988 challenging U.S. Patent 8,974,790, directed to methods of treating ulcerative colitis. Sandoz’s petitions identify a number of litigations and IPRs in which family members of the ‘737 and ‘790 patent are at issue.

These documents and other selected documents on IPRs filed on patents related to biologics are posted on our IPR tracker page.